Results 71 to 80 of about 13,617 (225)

Structure of the omalizumab Fab

, 2015
Omalizumab is a humanized anti-IgE antibody that inhibits the binding of IgE to its receptors on mast cells and basophils, thus blocking the IgE-mediated release of inflammatory mediators from these cells.
Andersen, Gregers Rom, Plum, Melanie, Tjerrild, Luna, Jakob, Thilo, Andersen, Gregers, Melanie Plum, Rasmus K. Jensen, Jensen, Rasmus K., Gregers Rom Andersen, Spillner, Edzard, Edzard Spillner, Luna Tjerrild, Thilo Jakob   +12 more
core   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Optimising the Diagnosis of Sesame Seed Allergy With the Basophil Activation Test

Allergy, EarlyView.
The basophil activation test (using the activation marker CD203c) was the only test able to both exclude and confirm sesame seed allergy with precision. A negative skin prick test to sesame extract or tahini and undetectable IgE to Ses i 1 could not rule out sesame seed allergy.
Ru‐Xin Foong, Irene Bartha, Holly Boyd, Andreina Marques‐Mejias, Suzana Radulovic, Marta Krawiec, Faye Harrison, Malak Eghleilib, Grammatiki Antoneria, Zainab Jama, Matthew Kwok, Vasco Claro, Cristian Ricci, Tom Marrs, Gideon Lack, George Du Toit, Alexandra F. Santos   +16 more
wiley   +1 more source

Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab can provide clinical benefits to a fraction of moderate-to-severe asthma patients. However, the mechanisms of action of omalizumab have not been fully understood.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Mark Millard, MD, Matthew Wiest, PhD, Chao Gu, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Omalizumab therapy for bullous pemphigoid

, 2014
BACKGROUND: Bullous pemphigoid (BP) responds to a variety of immunosuppressive agents and usually controls, but does not cure, the disease. Omalizumab, Food and Drug Administration—approved for asthma, selectively suppresses the activity of IgE, an ...
Kelly A.N. Messingham, Kenneth K. Yu, Ashley B. Crew, Crew, Ashley B., Messingham, Kelly A. N., David T. Woodley, Janet A. Fairley, Woodley, David T., Yu, Kenneth K., Fairley, Janet A.   +9 more
core   +1 more source

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

Фармакоэкономика, 2020
Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods.
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev   +2 more
doaj   +1 more source

Theraputic Use of Omalizumab in Allergic Asthma

, 2019
The monoclonal antibodies, especially omalizumab, are new drugs that are showing great efficacy in the treatment of standard drug resistance allergic asthma.
Pétursson, Magnús
core  

Kinetics of Antibody Responses and Effector Cell Sensitivity After High Dose Birch Extract Nasal Challenge

Allergy, EarlyView.
High‐dose birch‐extract nasal challenge induced synchronous peaks at 4 weeks in serum specific IgE (sIgE) and basophil sensitivity. Mast cell sensitivity via tSPT and sIgG1 and sIgG4 responses peaked later, at 6–8 weeks. Preseasonal allergen exposure attenuated seasonal sIgE increase and prevented further rise in tSPT sensitivity.
N. J. Campion, S. Villazala‐Merino, C. Morgenstern, L. Nemec, V. Stanek, A. Tu, M. Zghaebi, J. Toth, R. Fröschl, T. Perkmann, M. Bastl, K. Gangl, S. Schneider, H. Breiteneder, R. Ristl, M. Focke‐Tejkl, R. Valenta, V. Niederberger‐Leppin, J. Eckl‐Dorna   +18 more
wiley   +1 more source

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

Journal of Immunology Research, 2016
IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies ...
Arnau Navinés-Ferrer, Eva Serrano-Candelas, Gustavo-J Molina-Molina, Margarita Martín   +3 more
doaj   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source